THC acts as a high-potency, low-efficacy agent at the CB1 receptor, while CBD has many lower-potency targets — but the pharmacology of most phytocannabinoids, especially acid forms, remains poorly studied.
Cannabis pharmacology researchers, product developers, and anyone wanting deeper understanding of how different cannabinoids work
What the researchers found
Over 100 unique cannabinoid metabolites exist in cannabis, but pharmacological understanding is heavily concentrated on THC (CB1 partial agonist) and CBD (multiple low-potency targets), with acid phytocannabinoids particularly understudied.
Why it matters
Most cannabis science focuses on just two of 100+ compounds — understanding the full pharmacological landscape could unlock new therapeutic applications and explain the 'entourage effect.'
The numbers in context
Over 100 apparently unique cannabinoid metabolites identified in cannabis; THC is relatively high-potency but low-efficacy at CB1; CBD's molecular targets are lower potency with unclear human relevance.
How the study worked
Review of in vitro pharmacological data on plant-derived cannabinoids, assessing molecular targets, potency, and efficacy across the major and minor phytocannabinoid classes.
What this study cannot tell us
In vitro pharmacology often doesn't predict in vivo effects; many studies use non-physiological concentrations; acid cannabinoid data is particularly sparse.
How to read the evidence
Authoritative pharmacological review from a recognized cannabinoid researcher, grounded in in vitro data with acknowledged gaps in translation to human effects.
When this study was published
Published in 2026, providing a current assessment of the state of phytocannabinoid pharmacology research.
The bigger picture
The massive gap in our understanding of minor cannabinoids and acid forms (like THCA and CBDA) means we may be missing important therapeutic compounds hiding in plain sight in the cannabis plant.
Questions still open
- Which acid phytocannabinoids have the most therapeutic potential? Can the entourage effect be explained by specific minor cannabinoid-receptor interactions?
Common questions
How many active compounds are in cannabis?
What's the difference between how THC and CBD work?
Read the original research
The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.
Current topics in behavioral neurosciences, 76, 1-36
Citation
Alexander, Stephen P H. (2026). The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.. Current topics in behavioral neurosciences, 76, 1-36. https://doi.org/10.1007/7854_2025_605
Explore the wider topic
- THC Purity and Potency: What the Label Actually Means
- Dab and Concentrate Withdrawal: Why It Hits Harder
- Delta-8 THC: Addiction, Withdrawal, and What We Don't Know
- Edible Addiction and Withdrawal: What Makes It Different
- Edibles and Psychosis: When a Bad Trip Becomes an Emergency
- Vaping vs Smoking vs Edibles: A Harm Reduction Guide
- How Cannabis Products Are Made: From Plant to Concentrate to Edible
- Laced Weed and Contaminated Vapes: Real Risks vs Myths
- Legal vs Street Weed: Quality, Safety, and What You're Actually Smoking
- Quitting Weed Pens and Dabs: Why Concentrates Hit Different
- Quitting Edibles: Is Withdrawal Different from Smoking?
- Sativa vs Indica: The Myth and the Science Behind Cannabis Strain Labels
- Why Is Weed Withdrawal Worse Now Than 20 Years Ago?
- Resin vs Rosin vs Live Rosin: What's the Difference
- What Is Live Rosin and Why Is It So Expensive
- Terpenes Explained: Why Your Weed Smells Different and Why It Matters
- The Entourage Effect: Does Whole-Plant Cannabis Work Better Than Isolates
- Full Spectrum vs Broad Spectrum vs Isolate: What the Labels Mean